Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases
暂无分享,去创建一个
[1] I. Bassanetti,et al. Oxidative stress induced by copper and iron complexes with 8-hydroxyquinoline derivatives causes paraptotic death of HeLa cancer cells. , 2014, Molecular pharmaceutics.
[2] E. Taherian,et al. The biological and clinical activity of anti-malarial drugs in autoimmune disorders. , 2013, Current rheumatology reviews.
[3] H. Takayanagi,et al. Inhibitory effect of chloroquine on bone resorption reveals the key role of lysosomes in osteoclast differentiation and function , 2012 .
[4] N. Seidah,et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.
[5] A. Hoke,et al. Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graft‐versus‐host disease , 2005, American journal of hematology.
[6] Tingting Wang,et al. Hydroxychloroquine decreases the upregulated frequencies of Tregs in patients with oral lichen planus , 2014, Clinical Oral Investigations.
[7] D. Gladman,et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. , 2010, Arthritis and rheumatism.
[8] K. Batty,et al. Pharmacokinetics, Pharmacodynamics, and Allometric Scaling of Chloroquine in a Murine Malaria Model , 2011, Antimicrobial Agents and Chemotherapy.
[9] Changhai Chen. Development of antimalarial drugs and their application in China: a historical review , 2014, Infectious Diseases of Poverty.
[10] I. Marsol,et al. Antipalúdicos en dermatología: mecanismo de acción, indicaciones y efectos secundarios , 2014 .
[11] C. Evans,et al. Autophagy as a modulator and target in prostate cancer , 2014, Nature Reviews Urology.
[12] P. Saftig,et al. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function , 2009, Nature Reviews Molecular Cell Biology.
[13] U. Karaçayli,et al. Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome. , 2013, Oral health & preventive dentistry.
[14] M. V. Van Beek,et al. Antimalarials , 2001, Dermatologic clinics.
[15] A. Mahajan. Chapter-142 Treatment of Rheumatoid Arthritis State-of-the-Art , 2007 .
[16] F. Ascaso,et al. The "flying saucer" sign on spectral domain optical coherence tomography in chloroquine retinopathy. , 2013, Arthritis and rheumatism.
[17] S. Azar,et al. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role , 2014, Therapeutic advances in endocrinology and metabolism.
[18] R. Price,et al. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis , 2014, The Lancet. Infectious diseases.
[19] M. Luster,et al. Quinacrine-induced occlusive fibrosis in the human fallopian tube is due to a unique inflammatory response and modification of repair mechanisms. , 2013, Journal of reproductive immunology.
[20] A. Bridges,et al. Bullous rash and brown urine in a systemic lupus erythematosus patient treated with hydroxychloroquine. , 1995, Arthritis and rheumatism.
[21] R. Vollenhoven,et al. Treatment of rheumatoid arthritis: state of the art 2009 , 2009, Nature Reviews Rheumatology.
[22] N. Fazel. Cutaneous lichen planus: A systematic review of treatments , 2015, The Journal of dermatological treatment.
[23] T. Tenhave,et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. , 2011, Archives of dermatology.
[24] Y. Kato,et al. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI) , 2012, Modern rheumatology.
[25] N. Mar,et al. Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss , 2014, Journal of Thrombosis and Thrombolysis.
[26] N. Thomas,et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone , 2014, Current medical research and opinion.
[27] Shahjahan,et al. Reemergence of chloroquine (CQ) analogs as multi-targeting antimalarial agents: a review. , 2015, European journal of medicinal chemistry.
[28] D. Khan. Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use. , 2013, The journal of allergy and clinical immunology. In practice.
[29] N. Costedoat-Chalumeau,et al. Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? , 2015, Autoimmunity reviews.
[30] G. Doho,et al. Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine production. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[31] N. Shear,et al. Acute Generalized Exanthematous Pustulosis Induced by Hydroxychloroquine: First Case Report in Canada and Review of the Literature , 2013, Journal of cutaneous medicine and surgery.
[32] A. Gonzalez-Estrada,et al. Sporadic porphyria cutanea tarda: treatment with chloroquine decreases hyperglycemia and reduces development of metabolic syndrome. , 2014, European journal of internal medicine.
[33] D. Freeman,et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[34] V. Werth,et al. Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy , 2013, Dermatologic therapy.
[35] A. Fabre,et al. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review , 2013, European heart journal. Acute cardiovascular care.
[36] G. Oudit,et al. Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. , 2014, The Canadian journal of cardiology.
[37] H. Kushlaf. Emerging toxic neuropathies and myopathies. , 2011, Neurologic clinics.
[38] J. Grutters,et al. Cytotoxic agents in sarcoidosis: which one should we choose? , 2014, Current opinion in pulmonary medicine.
[39] K. McCrae,et al. Recent advances in the antiphospholipid antibody syndrome , 2014, Current opinion in hematology.
[40] K. Kirkwood,et al. Autoimmunity to deltaNp63alpha in Chronic Ulcerative Stomatitis , 2007, Journal of dental research.
[41] G. Chrousos,et al. New use for old drugs? Prospective targets of chloroquines in cancer therapy. , 2014, Current drug targets.
[42] E. Sausville,et al. Autophagy modulation: a target for cancer treatment development , 2015, Cancer Chemotherapy and Pharmacology.
[43] H. Sayles,et al. Associations of Hydroxychloroquine Use With Lipid Profiles in Rheumatoid Arthritis: Pharmacologic Implications , 2014, Arthritis care & research.
[44] L. Voinea,et al. Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review , 2014, Journal of medicine and life.
[45] P. Voulgari,et al. Effect of Hydroxychloroquine on the Lipid Profile of Patients with Sjögren Syndrome , 2014, The Journal of Rheumatology.
[46] J. Bargman,et al. The role of antimalarial agents in the treatment of SLE and lupus nephritis , 2011, Nature Reviews Nephrology.
[47] C. Mok,et al. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus , 2005, Lupus.
[48] M. Clowse,et al. Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature , 2014, Current opinion in rheumatology.
[49] R. López-Arellano,et al. Distribution of Hydroxychloroquine in Lymphoid Tissue in a Rabbit Model for HIV Infection , 2013, Antimicrobial Agents and Chemotherapy.
[50] R. Nosál',et al. Cationic amphiphilic drugs and platelet phospholipase A(2) (cPLA(2)). , 2002, Thrombosis research.
[51] Chih-Chuan Lin,et al. Chronic Hydroxychloroquine Use Associated with QT Prolongation and Refractory Ventricular Arrhythmia , 2006, Clinical toxicology.
[52] Nehal A. Shah,et al. Osseous sarcoidosis: clinical characteristics, treatment, and outcomes--experience from a large, academic hospital. , 2014, Seminars in arthritis and rheumatism.
[53] D. Gewirtz. The Autophagic Response to Radiation: Relevance for Radiation Sensitization in Cancer Therapy , 2014, Radiation research.
[54] M. Weisman,et al. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE , 2012, Nature Reviews Rheumatology.
[55] P. Ravaud,et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. , 2014, JAMA.
[56] P. Maes,et al. Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice , 2009, Antimicrobial Agents and Chemotherapy.
[57] M. Marmor,et al. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. , 2015, Ophthalmology.
[58] Razieh Soltani-Arabshahi,et al. Chloroquine/hydroxychloroquine‐induced pemphigus , 2006, International journal of dermatology.
[59] N. Gordon,et al. Autophagy in osteosarcoma. , 2014, Advances in experimental medicine and biology.
[60] P. Voulgari,et al. Inflammatory bowel disease and lupus: a systematic review of the literature. , 2012, Journal of Crohn's & colitis.
[61] W. A. S. Giraldo,et al. Hiperpigmentación cutánea generalizada y melanoniquia longitudinal secundarias al tratamiento con hidroxicloroquina en lupus eritematoso sistémico , 2013 .
[62] M. Figgie,et al. Surgical management of the juvenile idiopathic arthritis patient with multiple joint involvement. , 2014, The Orthopedic clinics of North America.
[63] J. Guilhou,et al. Severe mucocutaneous necrotizing vasculitis associated with the combination of chloroquine and proguanil. , 2003, Acta dermato-venereologica.
[64] J. Ramires,et al. Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[65] D. Cohen,et al. The Natural History of Chronic Actinic Dermatitis: An Analysis at a Single Institution in the United States , 2014, Dermatitis : contact, atopic, occupational, drug.
[66] M. Coutinho,et al. Hydroxychloroquine ototoxicity in a child with idiopathic pulmonary haemosiderosis. , 2002, International journal of pediatric otorhinolaryngology.
[67] C. Onyeji,et al. Pharmacokinetic aspects of chloroquine-induced pruritus: influence of dose and evidence for varied extent of metabolism of the drug. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[68] Isabel M. Vincent,et al. Metabolomic-Based Strategies for Anti-Parasite Drug Discovery , 2015, Journal of biomolecular screening.
[69] M. Santiago,et al. Chloroquine ototoxicity , 2007, Clinical Rheumatology.
[70] L. Requena,et al. Wong’s dermatomyositis: a new case and review of the literature , 2013, International journal of dermatology.
[71] M. Khamashta,et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review , 2008, Annals of the rheumatic diseases.
[72] H. Walia,et al. Hydrochloroquine retinopathy: characteristic presentation with review of screening , 2013, Clinical Rheumatology.
[73] T. Andrews,et al. Psychiatric manifestations of primary Sjögren's syndrome: a case report and literature review , 2014, BMJ Case Reports.
[74] L. Xing,et al. Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. , 2014, The Journal of clinical investigation.
[75] R. Díaz-Molina,et al. [Effects of hydroxychloroquine on insulin sensitivity and lipid profile in patients with rheumatoid arthritis]. , 2013, Revista medica de Chile.
[76] Bryan M Bishop,et al. Potential and Emerging Treatment Options for Ebola Virus Disease , 2015, The Annals of pharmacotherapy.
[77] S. Kalia,et al. New concepts in antimalarial use and mode of action in dermatology , 2007, Dermatologic therapy.
[78] A. Wozniacka,et al. Optimal Use of Antimalarials in Treating Cutaneous Lupus Erythematosus , 2005, American journal of clinical dermatology.
[79] D. Raoult,et al. Tropheryma whipplei Endocarditis , 2013, Emerging infectious diseases.
[80] I. Bassukas,et al. Synthetic antimalarial drugs and the triggering of psoriasis – do we need disease‐specific guidelines for the management of patients with psoriasis at risk of malaria? , 2014, International journal of dermatology.
[81] R. Asero,et al. Treatment of Refractory Chronic Urticaria: Current and Future Therapeutic Options , 2013, American Journal of Clinical Dermatology.
[82] M. Gottesman,et al. Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.
[83] L. Vilá,et al. Multifocal osteonecrosis in systemic lupus erythematosus: case report and review of the literature , 2013, BMJ Case Reports.
[84] L. Arnaud,et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. , 2015, Autoimmunity reviews.
[85] M. Ward. Outcomes of hospitalizations for myocardial infarctions and cerebrovascular accidents in patients with systemic lupus erythematosus. , 2004, Arthritis and rheumatism.
[86] N. Costedoat-Chalumeau,et al. [Neonatal lupus syndrome: Literature review]. , 2015, La Revue de medecine interne.
[87] S. Holmes,et al. Frontal fibrosing alopecia: a review of 60 cases. , 2012, Journal of the American Academy of Dermatology.
[88] A. Laties,et al. Approaches for detecting lysosomal alkalinization and impaired degradation in fresh and cultured RPE cells: evidence for a role in retinal degenerations. , 2014, Experimental eye research.
[89] M. J. Leckie,et al. Stevens-Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis. , 2002, Rheumatology.
[90] A. Baibergenova,et al. Lichen planopilaris: update on pathogenesis and treatment. , 2013, Skinmed.
[91] J. Moss,et al. Optimizing treatments for lymphangioleiomyomatosis , 2012, Expert review of respiratory medicine.
[92] D. Kurahara,et al. Pulmonary Hemosiderosis in Children with Bronchopulmonary Dysplasia , 2014, Case reports in pediatrics.
[93] É. Oksenhendler,et al. Granulomatous Disease in CVID: Retrospective Analysis of Clinical Characteristics and Treatment Efficacy in a Cohort of 59 Patients , 2012, Journal of Clinical Immunology.
[94] A. Engel,et al. Teaching NeuroImages: Hydroxychloroquine-induced vacuolar myopathy , 2013, Neurology.
[95] E. Padilha,et al. Evaluation of Antimalarial Activity and Toxicity of a New Primaquine Prodrug , 2014, PloS one.
[96] E. Matteson,et al. Rheumatoid vasculitis: an update , 2015, Current opinion in rheumatology.
[97] M. Marmor,et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. , 2002, Ophthalmology.
[98] K. Hahm,et al. Chemoquiescence for Ideal Cancer Treatment and Prevention: Where Are We Now? , 2014, Journal of cancer prevention.
[99] K. Bentsi-Enchill. Pigmentary skin changes associated with ocular chloroquine toxicity in Ghana. , 1980, Tropical and geographical medicine.
[100] V. Werth,et al. Update on pathogenesis and treatment of CLE , 2013, Current opinion in rheumatology.
[101] F. Müller,et al. Molecular Mechanism of Renal Tubular Secretion of the Antimalarial Drug Chloroquine , 2011, Antimicrobial Agents and Chemotherapy.
[102] H. Schmid,et al. Chloroquine-induced phospholipidosis of the kidney mimicking Fabry's disease: case report and review of the literature. , 2003, Human pathology.
[103] R. Vij,et al. Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[104] F.C. Zhang,et al. An SLE patient with prolactinoma and recurrent granulomatous mastitis successfully treated with hydroxychloroquine and bromocriptine , 2014, Lupus.
[105] A. Krettli,et al. Antiplasmodial activity of chloroquine analogs against chloroquine-resistant parasites, docking studies and mechanisms of drug action , 2014, Malaria Journal.
[106] A. Chopra,et al. Effectiveness of Chloroquine and Inflammatory Cytokine Response in Patients With Early Persistent Musculoskeletal Pain and Arthritis Following Chikungunya Virus Infection , 2014, Arthritis & rheumatology.
[107] N. Costedoat-Chalumeau,et al. Hydroxychloroquine: a multifaceted treatment in lupus. , 2014, Presse medicale.
[108] S. Dhaneshwar,et al. An update on disease modifying antirheumatic drugs. , 2014, Inflammation & allergy drug targets.
[109] S. Prusiner,et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease , 2013, Neurology.
[110] A. Chauhan,et al. Endocytosis of human immunodeficiency virus 1 (HIV-1) in astrocytes: a fiery path to its destination. , 2015, Microbial pathogenesis.
[111] G. Forloni,et al. Therapy in prion diseases. , 2013, Current topics in medicinal chemistry.
[112] K. Gurova,et al. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. , 2009, Future oncology.
[113] J. Wenzel,et al. Innate Immune-Response Mechanisms in Dermatomyositis: An Update on Pathogenesis, Diagnosis and Treatment , 2014, Drugs.
[114] J. Nunemacher,et al. Optimal management of giant cell arteritis and polymyalgia rheumatica , 2012, Therapeutics and clinical risk management.
[115] R. Wolf,et al. Antimalarials: unapproved uses or indications. , 2000, Clinics in dermatology.
[116] W. S. Sifuentes Giraldo,et al. Generalized skin hyperpigmentation and longitudinal melanonychia secondary to treatment with hydroxychloroquine in systemic lupus erythematosus. , 2013, Reumatologia clinica.
[117] R. Flipo,et al. Treatment of Nongout Joint Deposition Diseases: An Update , 2014, Arthritis.
[118] W. Peitsch,et al. Individualizing treatment and choice of medication in lichen planus: a step by step approach , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[119] A. Chopra,et al. Psychosis likely induced by hydroxychloroquine in a patient with chronic Q fever: a case report and clinically relevant review of pharmacology. , 2014, Psychosomatics.
[120] A. Bhalla,et al. Hydroxychloroquine’s Efficacy as an Antiplatelet Agent Study in Healthy Volunteers , 2015, Journal of cardiovascular pharmacology and therapeutics.
[121] A. Carmichael,et al. Fatal toxic epidermal necrolysis associated with hydroxychloroquine , 2001, Clinical and experimental dermatology.
[122] G. Stark,et al. Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer , 2014, Molecular Cancer Therapeutics.
[123] N. Sharma,et al. Unusual life-threatening adverse drug effects with chloroquine in a young girl. , 2003, Journal of postgraduate medicine.
[124] M. González-Ortiz,et al. Efecto de la hidroxicloroquina sobre la sensibilidad a la insulina y el perfil de lípidos en pacientes con artritis reumatoide , 2013 .
[125] S. Wahie,et al. Long‐term response to hydroxychloroquine in patients with discoid lupus erythematosus , 2013, The British journal of dermatology.
[126] Duxin Sun,et al. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel. , 2013, Biomaterials.
[127] Jeffrey P Krise,et al. Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. , 2007, Journal of pharmaceutical sciences.
[128] A. Escobedo,et al. Management of chronic Giardia infection , 2014, Expert review of anti-infective therapy.
[129] L. Sammaritano,et al. Rheumatoid arthritis medications and lactation , 2014, Current opinion in rheumatology.
[130] R. Kandolf,et al. Chloroquine cardiomyopathy – a review of the literature , 2013, Immunopharmacology and immunotoxicology.
[131] N. Morrell,et al. Chloroquine Prevents Progression of Experimental Pulmonary Hypertension via Inhibition of Autophagy and Lysosomal Bone Morphogenetic Protein Type II Receptor Degradation , 2013, Circulation research.
[132] I. Olivieri,et al. An update on the management of hepatitis C virus-related arthritis , 2014, Expert opinion on pharmacotherapy.
[133] J. Piette,et al. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. , 2013, JAMA dermatology.
[134] I. B. Marsol,et al. Antimalarials in dermatology: mechanism of action, indications, and side effects. , 2014, Actas dermo-sifiliograficas.
[135] C. Hewitt,et al. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial , 2013, Trials.